DOLK: A Protein Understudied for Alzheimer's and Cancer (G22845)

Target Name: DOLK

NCBI ID: G22845

DOLK

DOLK: A Protein Understudied for Alzheimer's and Cancer

DOLK (DOLK-HUMAN) is a protein that is expressed in the human placenta, and it is associated with various health conditions, including cancer, diabetes, and obesity. It is also been found to be highly expressed in the brains of individuals with Alzheimer's disease.

Recent studies have shown that DOLK is involved in many different processes in the body, including the regulation of cell growth, differentiation, and survival. It has also been shown to play a role in the development and progression of various diseases, including cancer, diabetes, and Alzheimer's disease.

One of the main reasons for the interest in DOLK is its potential as a drug target or biomarker. Because DOLK is involved in many different processes in the body, it is a promising target for the development of new treatments for a wide range of diseases.

One of the ways that DOLK is being targeted for drug development is through its role in cancer. DOLK has been shown to be involved in the regulation of cell growth and survival in cancer cells, and it is thought to be a useful target for drugs that can inhibit these processes.

For example, a team of researchers at the University of California, San Diego found that DOLK was highly expressed in cancer cells and that inhibiting its activity could significantly reduce the growth of these cells. They also found that DOLK was a strong predictor of the effectiveness of certain anti-cancer drugs, suggesting that it may be a useful biomarker for the evaluation of cancer treatments.

In addition to its potential as a cancer drug target, DOLK is also being targeted for its potential as a biomarker for the diagnosis and progression of Alzheimer's disease. As mentioned earlier, DOLK is highly expressed in the brains of individuals with Alzheimer's disease, and it is thought to play a role in the development and progression of this disease.

One of the ways that DOLK is being targeted for use as an Alzheimer's disease biomarker is through its ability to be used as a diagnostic tool. By analyzing the levels of DOLK in brain tissue samples from individuals with Alzheimer's disease, researchers are able to determine the severity of the disease and track its progression over time.

Another way that DOLK is being targeted for use as an Alzheimer's disease biomarker is through its ability to be used as a target for new therapies. Researchers are working to develop drugs that can specifically target DOLK and inhibit its activity in the brains of individuals with Alzheimer's disease.

Overall, DOLK is a protein that is being studied for its potential as a drug target and biomarker in the context of Alzheimer's disease and other serious health conditions. Further research is needed to fully understand its role and potential as a new treatment option.

Protein Name: Dolichol Kinase

Functions: Catalyzes CTP-mediated phosphorylation of dolichol, the terminal step in de novo dolichyl monophosphate (Dol-P) biosynthesis (PubMed:12213788, PubMed:16923818, PubMed:17273964). Dol-P is a lipid carrier essential for the synthesis of N-linked and O-linked oligosaccharides and for GPI anchors (PubMed:12213788)

The "DOLK Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DOLK comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets